Hepion Pharmaceuticals Inc

NASDAQ:HEPA  
0.59
+0.02 (+3.06%)
Products

Hepion Pharmaceuticals Receives FDA Orphan Drug Status Designation For Rencofilstat For The Treatment Of Hepatocellular Carcinoma

Published: 06/20/2022 12:59 GMT
Hepion Pharmaceuticals Inc (HEPA) - Hepion Pharmaceuticals Receives FDA Orphan Drug Status Designation for Rencofilstat for the Treatment of Hepatocellular Carcinoma.